The New Eugenics: The Case Against Genetically Modified Humans
By Marcy Darnovsky,
Different Takes (Spring 2000)
| 11. 30. 1999
Published by the Hampshire College Population and Development Program
At the cusp of dot-com frenzy and the biotech century, a group of influential scientists and pundits has begun zealously promoting a new bio-engineered utopia. In the world of their visionary fervor, parents will strive to afford the latest genetic "improvements" for their children. According to the advocates of this human future (or, as some term it, "post-human" future), the exercise of consumer preferences for offspring options will be the prelude to a grand achievement: the technological control of human evolution.
My first close encounter with this techno-eugenic enthusiasm was in a 1997 book written for an unconverted lay audience by Princeton geneticist Lee M. Silver. In Remaking Eden: Cloning and Beyond in a Brave New World (New York: Avon Books 1998), Silver spins out scenarios of a future in which affluent parents are as likely to arrange genetic enhancements for their children as to send them to private school.
Silver confidently predicts that upscale baby-making will soon take place in fertility clinics, where prospective parents will undergo an IVF procedure...
Related Articles
By Liyan Qi and Jonathan Cheng, The Wall Street Journal | 03.26.2025
photo via Wikimedia Commons licensed under CC by 3.0
Chinese scientist He Jiankui set off global outrage and landed in prison after he skirted ethical guidelines and claimed he had produced genetically modified babies designed to resist HIV infection.
Now, the self-styled ...
By Anna Louie Sussman, The New York Times | 03.25.2025
On June 24, 2022, the same day the Supreme Court issued its decision in Dobbs v. Jackson Women’s Health Organization, I received a call from the fertility clinic where I’d been undergoing in vitro fertilization, informing me that seven of...
By Michael Gibney, PharmaVoice | 03.20.2025
The death this week of a teenager receiving Sarepta Therapeutics’ gene therapy Elevidys for Duchenne muscular dystrophy is a tragic reminder of the stakes involved in cutting-edge biotech innovation.
While gene therapies like Sarepta’s offer an opportunity to treat and...
By Staff, The Medicine Maker | 03.21.2025
"The Promise and Peril of CRISPR" cover by Johns Hopkins University Press
As a paediatrician taking care of children with sickle cell disease, Neal Baer, a Harvard Medical School graduate, was in awe of the power of CRISPR technologies. Later...